Bevatas 100 mg Injection USA | Bulk Oncology Exporter from India

Bevatas 100 mg Injection: Advanced Anti-VEGF Therapy for Targeted Cancer Care

Are you looking for a reliable Bevatas 100 mg injection exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a leading global supplier and bulk distributor of specialized oncology biologics. We provide a regulatory-compliant, cold-chain-secured supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving Bevacizumab therapies reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Bevatas 100 mg?

Bevatas 100 mg Injection is a recombinant humanized monoclonal antibody containing the active ingredient Bevacizumab. Manufactured by Intas Pharmaceuticals Ltd., Bevatas is a high-quality biosimilar designed to provide clinical efficacy and safety equivalent to the reference product Avastin.

For international B2B procurement, Bevatas 100 mg (supplied as a 100 mg/4 ml solution in a single-dose vial) is a cornerstone of modern oncology, used to inhibit the growth of tumors by restricting their blood supply.

Primary Therapeutic Indications

Bevatas 100 mg is clinically utilized across the globe for:

1. Metastatic Colorectal Cancer (mCRC): First or second-line treatment in combination with chemotherapy.

2. Non-Small Cell Lung Cancer (NSCLC): Specifically for unresectable, advanced, or metastatic non-squamous types.

3. Glioblastoma: For adult patients with progressive disease following prior therapy.

4. Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon-alpha.

5. Cervical and Ovarian Cancers: For advanced, recurrent, or metastatic stages.

Mechanism of Action: The Science of Angiogenesis Inhibition

Bevatas works through a sophisticated mechanism known as anti-angiogenesis:

• VEGF Binding: The Bevacizumab molecule selectively binds to vascular endothelial growth factor (VEGF), a protein that signals the body to grow new blood vessels.

• Starving the Tumor: By neutralizing VEGF, Bevatas prevents the tumor from forming its own network of blood vessels. Without a dedicated blood supply, the tumor is "starved" of the oxygen and nutrients it needs to grow.

• Vascular Normalization: It also helps "normalize" existing tumor vessels, making them less leaky and lowering the pressure inside the tumor, which allows other chemotherapy drugs to reach the cancer cells more effectively.

Administration and Clinical Safety

• Administration: Bevatas must be administered as an intravenous (IV) infusion by a healthcare professional. It is not suitable for IV push or bolus.

• Storage Requirements: This biological product requires a strict cold chain at 2°C to 8°C (36°F to 46°F). Do not freeze or shake, and protect from light.

• Key Safety Monitoring:

• Gastrointestinal Perforation: Patients should be monitored for signs of abdominal pain.

• Wound Healing: Therapy should not be started within 28 days following major surgery.

• Hypertension: Blood pressure should be monitored regularly during treatment.

Why Source Bevatas from Ernest Oncology?

• Authentic Indian Exporter: We provide direct access to genuine Intas Pharmaceuticals inventory, ensuring 100% product authenticity and competitive wholesale pricing.

• Validated Cold-Chain Logistics: We utilize specialized thermal packaging and real-time monitoring to ensure the stability of Bevacizumab during transit to the USA, UK, Australia, and South Africa.

• Regulatory Support: We provide all necessary B2B documentation, including GMP compliance certificates, batch-specific COAs, and export permits.

• Bulk Supply Reliability: We specialize in fulfilling large-scale orders for hospital networks, oncology clinics, and regional pharmaceutical distributors.